Cyclerion Therapeutics, Inc.CYCNNASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank63
3Y CAGR-13.1%
5Y CAGR+3.8%
Year-over-Year Change
Price-to-book ratio
3Y CAGR
-13.1%/yr
Annual compound
5Y CAGR
+3.8%/yr
Recent deceleration
Percentile
P63
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2024 | 0.92 | +32.0% |
| 2023 | 0.69 | -74.6% |
| 2022 | 2.73 | +95.5% |
| 2021 | 1.40 | -10.8% |
| 2020 | 1.56 | +105.2% |
| 2019 | 0.76 | +102.3% |
| 2018 | -32.68 | +18.0% |
| 2017 | -39.84 | - |
| 2016 | 0.00 | - |